Hexazinone (active ingredient) was aerially applied as a pellet (Velpar ULW) and as a liquid (Velpar L) to watersheds in the Piedmont of Alabama, U.S.A., at the rate of 6.72 kg·ha -1 (three times the prescribed rate for this site). An untreated watershed served as a control. We determined hexazinone half-life in days for Velpar ULW (plants, 26-59; litter, 55; bare soil, 68; soil under litter, 74) and for Velpar L (plants, 19-36; litter, 56; bare soil, 77; soil under litter, 275). Maximum stream concentrations of hexazinone (422 µg·L -1 for Velpar ULW; 473 µg·L -1 for Velpar L) were observed during application and resulted from direct overspray. Hexazinone stream concentrations peaked several times during stormflow in the first 30 days (56-70 µg·L -1 for Velpar ULW; 145-230 µg·L -1 for Velpar L) and were diluted three to five times 1.6 km downstream. Hexazinone metabolites were also monitored. Exposure of macroinvertebrates to hexazinone did not alter benthic community structure. Taxa richness, including pollution-sensitive insects, did not differ significantly between either hexazinone treatment and the control. Benthic macroinvertebrates in Piedmont streams of the southeastern United States appear insensitive to hexazinone at the exposures observed in this study.Résumé : De l'hexazinone (ingrédient actif) a été appliqué par voie aérienne sous formes granulaire (Velpar ULW) et liquide (Velpar L) dans des bassins versants du piémont de l'Alabama, aux États-Unis, au taux de 6,72 kg·ha -1 , c'est-àdire trois fois le taux recommandé pour ce site. Un bassin versant non traité a servi de témoin. Nous avons déterminé la demi-vie en jours de l'hexazinone pour le Velpar ULW
High-pressure liquid chromatography in combination with field desorption mass spectrometry as techniques of high specificity and sensitivity have been applied to the identification and quantitation of the anticancer drug methotrexate and its metabolites which occur in clinical high-dose therapy. Field desorption mass spectra of methotrexate and several methotrexate and folic acid derivatives, when investigated as free acids or ammonium salts, yield abundant protonated molecular ions and a consistent pattern of structurally significant fragments. High-pressure liquid chromatographic separation of methotrexate metabolites was performed on reverse-phase, C-18 columns using a volatile, ammonium bicarbonate/acetate containing mobile phase that was especially suited for the field desorption mass spectral analysis of isolated metabolites, and provided the definite identification of 7-hydroxymethotrexate and 4-[[2,4-diamino-6-pteridinyl]methyl]methylamino]-benzoic acid in serum and urine of patients treated with high-dose methotrexate. The high intensity and stability of the [MH]+ ions was found suitable for the quantitation of methotrexate and related folate analogues by field desorption mass spectrometry. A synthetic methotrexate derivative, methotrexate-gamma-(2-hydroxy)ethyl-amide was used as internal standard for the quantitative determination of methotrexate in serum and urine. In a study to comparatively assess the potential of specific quantitation methods, serum and urine levels of methotrexate and its major metabolite, 7-hydroxymethotrexate were determined by (i) an enzyme immunoassay, (ii) reverse phase high-pressure liquid chromatography and (iii) field desorption mass spectrometry. Results obtained from four patients with osteogenic sarcoma receiving high-dose methotrexate/leucovorin rescue therapy consistently show the sustained elimination of 7-hydroxymethotrexate over several days, thus indicating the utility of specifically monitoring this nephrotoxic metabolite, at massive methotrexate doses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.